ISPCNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
iSpecimen Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.91−0.01 (-0.75%)
Close on Oct 19, 2026
- Market cap
- $1.27M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2019 to 2025
Gross margin
11.2%−45.0 pts over 5 years
Operating margin
-465.4%−436.0 pts over 5 years
Net margin
-543.7%−486.8 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -79.2% | -43.0% | -25.1% | – | |
| Gross profit | -94.8% | -66.3% | -45.8% | – |
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 18.6% | -327.8% | |
| Return on assets | – | – | -111.1% | |
| Current ratio | – | 0.16 | 1.12 | |
| Interest coverage | – | -1.1× | -4606.4× | |
| Capex to revenue | – | 0.0% | 0.0% | |
| Diluted shares | – | 0M | 0M |
Where the cash went
Fiscal 2021 to 2025, five years combined
iSpecimen generated $34.80M from operations and spent $269.53K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$34.80M
Used
$269.53K
Capital expenditure$269.53K100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-543.7%
×Asset turnover0.20×
×Equity multiplier2.95×
=Return on equity, FY2025-327.8%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -543.7% | 0.20× | 2.95× | -327.8% |
| FY2024 | -134.5% | 0.74× | 1.93× | -191.5% |
| FY2023 | -111.8% | 0.49× | 1.35× | -73.9% |
| FY2022 | -98.5% | 0.34× | 1.20× | -40.9% |
| FY2021 | -80.5% | 0.53× | 16.68× | -713.1% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$10.49M
- Cash generatingOperating cash flow above zero-$4.24M
- Return on assets improvedROA up on the prior year-79.0% → -112.2%
- Earnings backed by cashOperating cash flow above net income-$4.24M vs -$10.49M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose0.62 → 1.12
- No dilutionShare count did not rise0M → 0M
- Gross margin improvedGross margin up on the prior year44.99% → 11.18%
- More efficientAsset turnover rose0.59 → 0.21